Literature DB >> 11400125

Periodate-mediated glycosaminoglycan stabilization in bioprosthetic heart valves.

J Lovekamp1, N Vyavahare.   

Abstract

Bioprosthetic heart valves (BPHVs) derived from glutaraldehyde-crosslinked porcine aortic valves are frequently used in heart valve replacement surgeries. However, the majority of bioprostheses fail clinically because of calcification and degeneration. We have recently shown that glycosaminoglycan (GAG) loss may be in part responsible for degeneration of glutaraldehyde-crosslinked bioprostheses. In the present studies, we used a mild reaction of periodate-mediated crosslinking to stabilize glycosaminoglycans in the bioprosthetic tissue. We demonstrate the feasibility of periodate reaction by crosslinking major components of extracellular matrix of bioprosthetic heart valve tissue, namely type I collagen and hyaluronic acid (HA). Uronic acid assay of periodate-fixed HA-collagen matrices showed 48% of HA disaccharides were bound to collagen. Furthermore, we show that such reactions are also feasible to fix glycosaminoglycans present in the middle spongiosa layer of bioprosthetic heart valves. The periodate reactions were compatible with conventional glutaraldehyde crosslinking and showed adequate stabilization of extracellular matrix as demonstrated by thermal denaturation temperature and collagenase assays. Moreover, uronic acid assays of periodate-fixed BPHV cusps showed 36% reduction in the amount of unbound GAG disaccharides as compared with glutaraldehyde-crosslinked cusps. We also demonstrate that calcification of BPHV cusps was significantly reduced in the periodate-fixed group as compared with the glutaraldehyde-fixed group in 21-day rat subdermal calcification studies (periodate-fixed tissue Ca 72.01 +/- 5.97 microg/mg, glutaraldehyde-fixed tissue Ca 107.25 +/- 6.56 microg/mg). We conclude that periodate-mediated GAG fixation could reduce structural degeneration of BPHVs and may therefore increase the useful lifetime of these devices. Copyright 2001 John Wiley & Sons, Inc. J Biomed Mater Res 56: 478--486, 2001

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400125     DOI: 10.1002/1097-4636(20010915)56:4<478::aid-jbm1119>3.0.co;2-c

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  7 in total

1.  Exogenous hyaluronic acid and chondroitin sulfate crosslinking treatment for increasing the amount and stability of glycosaminoglycans in bioprosthetic heart valves.

Authors:  Yang Lei; Qinggong Ning; Yuyang Tang; Yunbing Wang
Journal:  J Mater Sci Mater Med       Date:  2019-03-06       Impact factor: 3.896

2.  Stability and function of glycosaminoglycans in porcine bioprosthetic heart valves.

Authors:  Joshua J Lovekamp; Dan T Simionescu; Jeremy J Mercuri; Brett Zubiate; Michael S Sacks; Narendra R Vyavahare
Journal:  Biomaterials       Date:  2005-09-06       Impact factor: 12.479

3.  Neomycin prevents enzyme-mediated glycosaminoglycan degradation in bioprosthetic heart valves.

Authors:  Devanathan Raghavan; Dan T Simionescu; Naren R Vyavahare
Journal:  Biomaterials       Date:  2007-03-13       Impact factor: 12.479

4.  Effects of cyclic flexural fatigue on porcine bioprosthetic heart valve heterograft biomaterials.

Authors:  Ali Mirnajafi; Brett Zubiate; Michael S Sacks
Journal:  J Biomed Mater Res A       Date:  2010-07       Impact factor: 4.396

5.  Neomycin binding preserves extracellular matrix in bioprosthetic heart valves during in vitro cyclic fatigue and storage.

Authors:  Devanathan Raghavan; Barry C Starcher; Naren R Vyavahare
Journal:  Acta Biomater       Date:  2008-11-27       Impact factor: 8.947

6.  Effects of Leaflet Stiffness on In Vitro Dynamic Bioprosthetic Heart Valve Leaflet Shape.

Authors:  Hiroatsu Sugimoto; Michael S Sacks
Journal:  Cardiovasc Eng Technol       Date:  2013-03       Impact factor: 2.495

7.  Neomycin and pentagalloyl glucose enhanced cross-linking for elastin and glycosaminoglycans preservation in bioprosthetic heart valves.

Authors:  Daniel R Tripi; Naren R Vyavahare
Journal:  J Biomater Appl       Date:  2014-01       Impact factor: 2.646

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.